← Back to Search

Immunomodulatory Agent

CC-122 for Non-Hodgkin's Lymphoma

Phase 1

Waitlist Available

Research Sponsored by Bristol-Myers Squibb

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to approximately 3 years

Awards & highlights

Study Summary

This trial researches safety & benefits of a treatment (CC-122) for people who have been receiving it for 5+ years & have seen clinical benefit.

Who is the study for?

This trial is for people with Non-Hodgkin's Lymphoma who are already participating in other CC-122 studies and benefiting from the treatment without experiencing disease progression or reasons to stop as per previous study rules.Check my eligibility

What is being tested?

The trial continues providing a drug called CC-122 to participants from earlier trials. It aims to understand long-term safety and how well patients tolerate continued use of this medication over time.See study design

What are the potential side effects?

While specific side effects aren't listed, they will monitor how the body handles CC-122, which may include tracking any adverse reactions or discomforts that arise during extended treatment.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to approximately 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to approximately 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of deaths for participants who received at least 1 dose of CC-122

Number of participants with serious adverse events (SAEs) for participants who received at least 1 dose of CC-122

Trial Design

1Treatment groups

Experimental Treatment

Group I: CC-122 and DexamethasoneExperimental Treatment2 Interventions

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

CC-122

2015

Completed Phase 2

~670

Dexamethasone

2007

Completed Phase 4

~2590

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor

2,638 Previous Clinical Trials

4,128,502 Total Patients Enrolled

Media Library

CC-122 (Immunomodulatory Agent) Clinical Trial Eligibility Overview. Trial Name: NCT05688475 — Phase 1

Non-Hodgkin's Lymphoma Research Study Groups: CC-122 and Dexamethasone

Non-Hodgkin's Lymphoma Clinical Trial 2023: CC-122 Highlights & Side Effects. Trial Name: NCT05688475 — Phase 1

CC-122 (Immunomodulatory Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05688475 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What risks are associated with the usage of CC-122 and Dexamethasone?

"As this is an early stage Phase 1 clinical trial, both CC-122 and Dexamethasone were given a safety ranking of 1 – reflecting the limited data available to support their efficacy."

Answered by AI

Are there any locations in North America conducting this clinical experiment?

"This ongoing trial has 4 sites, which are situated in Nashville, Madison and Toronto. Additionally, there are a few more locations to choose from if you intend to take part. It is best practice to select the one nearest your home so as to minimize traveling needs during participation."

Answered by AI

Are participants being recruited for this research endeavor?

"Unfortunately, information on clinicaltrials.gov affirms that this medical trial is not currently seeking any more individuals to participate. The study was initially posted in February 2023 and the last update occurred 4 days prior to this answer; however, there are 1745 other studies with open recruitment at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Rollover Study of CC-122

2023. "A Rollover Study of CC-122". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05688475.